Drug development: Raise standards for preclinical cancer research

@article{Begley2012DrugDR,
  title={Drug development: Raise standards for preclinical cancer research},
  author={C. Glenn Begley and Lee M. Ellis},
  journal={Nature},
  year={2012},
  volume={483},
  pages={531-533}
}
C. Glenn Begley and Lee M. Ellis propose how methods, publications and incentives must change if patients are to benefit. 
Drug therapy: Preclinical oncology — reporting transparency needed
TLDR
A meta-analysis of preclinical experiments that examined the efficacy of sunitinib demonstrates how suboptimal preclinical study designs can prompt unwarranted clinical expectations.
Correction: A standardised framework to identify optimal animal models for efficacy assessment in drug development
TLDR
This research presents a novel probabilistic procedure that allows for direct measurement of the response of the immune system to earthquake-triggered landsliding.
In search of preclinical robustness
Systematic engagement of statisticians in preclinical research could help address the weaknesses that are undermining the likelihood of subsequent success in drug discovery and development.
Limits to Personalized Cancer Medicine.
TLDR
The authors argue that the principles of clinical investigation need to be applied to address the many unanswered questions in personalized oncology.
Preclinical research: Make mouse studies work.
More investment to characterize animal models can boost the ability of preclinical work to predict drug effects in humans, says Steve Perrin.
Misleading mouse studies waste medical resources
Retrospective of more than 100 failed drugs show many should have never made it to clinical trials.
Communication in Drug Development: “Translating” Scientific Discovery
TLDR
This Commentary identifies key elements of communication required to successfully translate promising biological findings to novel approved drug therapies and discusses the attendant challenges and opportunities.
Lost in the citation valley
Changing the academic reward system to improve translational medicine should start by moving away from a myopic focus on publications.
Irreproducible biology research costs put at $28 billion per year
Study calculates cost of flawed biomedical research in the United States.
Novel Targets and Their Assessment for Cancer Treatment
TLDR
As drug discovery in this field accelerates, the field must focus on human-based biology and build out the appropriate set of tools in order to assess new targets and to predict efficacy in the clinic.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 10 REFERENCES
Drug development and clinical trials—the path to an approved cancer drug
TLDR
This Review highlights new approaches in preclinical and clinical drug development that will help accelerate approval of drugs, and aim to provide more-effective treatments alongside companion diagnostic tests to ensure the right treatment is given to the right patient.
Raising the bar for cancer therapy models
TLDR
The authors find close, if not compelling, correlations between the clinical trial outcomes and the corresponding GEMM therapy results in most, though not all, of their models using the same or very similar treatment regimens.
High drug attrition rates—where are we going wrong?
TLDR
The reasons for this high attrition rate are complex; however, several articles in this issue provide insights into why this is occurring and the importance of identifying and validating the target and understanding resistance mechanisms.
Believe it or not: how much can we rely on published data on potential drug targets?
1. This indicates the limitations of the predictivity of disease models and also that the validity of the targets being investigated is frequently questionable, which is a crucial issue to address if
Do Pressures to Publish Increase Scientists' Bias? An Empirical Support from US States Data
TLDR
The hypothesis that competitive academic environments increase not only scientists' productivity but also their bias is verified, which might be observed in other countries where academic competition and pressures to publish are high.
Nature Rev. Clin. Oncol
  • Nature Rev. Clin. Oncol
  • 2012
Nature Rev. Clin. Oncol
  • Nature Rev. Clin. Oncol
  • 2011
Nature Rev. Drug Discov
  • Nature Rev. Drug Discov
  • 2011
Nature Biotechnol
  • Nature Biotechnol
  • 2010
PLoS ONE
  • PLoS ONE
  • 2010